To The Moon

Thinking about what to do with Pfizer stock right now? You’re not alone, and frankly, it’s been a fascinating ride. After lagging for much of the past three years, Pfizer’s share price has shown a subtle change in mood lately. The stock edged up 1.3% over the last week and 3.4% this past month, which might catch your eye, especially after a rocky year marked by a -6.6% dip year-to-date and a -7.8% slide over the last twelve months. Those numbers might look daunting, but every story has more than one chapter.

There’s more at play than just sentiment. Key partnerships on new drug development and several pipeline updates have provided fresh optimism, hinting at growth potential beyond the COVID era. Yet, the shadow of long-term underperformance lingers, with the stock down nearly 36% over three years. It’s a mix of renewed hope and cautious realism, which makes Pfizer so interesting for value-focused investors.

But are the current headlines, price moves, and changing risk perceptions accounted for in Pfizer’s valuation? Turns out, the company passes 5 out of 6 major undervaluation checks, earning it an impressive value score of 5. Next, let’s break down exactly how Pfizer stacks up across classic valuation approaches, and why there might be an even better way to judge its true worth at the end of this article.

Approach 1: Pfizer Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow (DCF) model estimates a company's true worth by projecting its expected cash profits into the future and bringing those back to today's value. This approach relies on the logic that a business is ultimately worth the sum of all its future cash flows, adjusted for time and risk.

For Pfizer, analysts currently estimate Free Cash Flow at around $12.0 Billion per year. Looking ahead, consensus forecasts expect this to grow steadily, reaching approximately $16.8 Billion in 2029. I then extends these estimates out another five years using moderate growth assumptions, showing sustained strength in Pfizer's cash generation.

According to this DCF model, Pfizer's fair value comes in at $68 per share. With the stock currently trading at a steep discount, this represents a calculated undervaluation of 63.4 percent, which is a significant gap. The implication is clear: Based on cash flow potential alone, Pfizer appears much cheaper than its long-term prospects suggest.

Result: UNDERVALUED

PFE Discounted Cash Flow as at Oct 2025

My Discounted Cash Flow (DCF) analysis suggests Pfizer is undervalued by 63.4%.

Approach 2: Pfizer Price vs Earnings

The Price-to-Earnings (PE) ratio is a time-tested metric for evaluating profitable companies like Pfizer because it shows how much investors are paying today for each dollar of current earnings. This makes it particularly useful when a company’s earnings are steady and transparent, as is typically the case in the pharmaceutical sector.

What makes a “normal” PE ratio can vary, influenced by factors like a company's growth prospects, the stability of its revenue, and the broader risks facing its industry. Higher growth or lower risk tends to justify a higher PE ratio, while slumping growth or rising risk can drag it down.

Pfizer currently trades at a PE ratio of 13.2x. For context, the average for its pharmaceutical industry peers stands at around 18.6x, and the broader industry itself averages about 18.6x as well. This means Pfizer is well below both peer and industry benchmarks, initially suggesting a discount.

However, I digged deeper by blending company-specific growth forecasts, profit margins, risk levels, and market size into a custom benchmark. In Pfizer’s case, the Fair PE Ratio is calculated at 22.3x, significantly higher than the current ratio. By accounting for more than just averages, the Fair Ratio offers a much clearer picture of what Pfizer’s shares should reasonably trade at, given everything that makes it unique.

Since Pfizer’s actual PE ratio is considerably below its Fair Ratio, the analysis again points to the stock being undervalued at current prices.

Result: UNDERVALUED

NYSE:PFE PE Ratio as at Oct 2025

$Pfizer(PFE)$ $Johnson & Johnson(JNJ)$ $Moderna, Inc.(MRNA)$ $Ocugen(OCGN)$ $Novavax(NVAX)$